Importantly, our study provides additional evidence to support the use of basal LIPI score and PD1 mRNA in tumor tissue at least to select patients for clinical trials with anti-PD1/PD-L1 ICI and/or as stratification factors, while PD-L1%, with a potential 10% cut-off, is a promising tumor-agnostic prognostic and predictive factor. Here, CD274 is linked to neoplasm.